Trial Search Results

A Study of a Levonorgestrel-Releasing Intrauterine System for Long-Term, Reversible Contraception

The primary objective of this study is to assess the efficacy of a levonorgestrel-releasing intrauterine system (LNG20) in nulliparous and parous females of child-bearing potential who request long-term, reversible contraception for up to 10 years.

Stanford is currently accepting patients for this trial.

Lead Sponsor:

Medicines360

Stanford Investigator(s):

Intervention(s):

  • Drug: LNG20
  • Drug: Mirena

Phase:

Phase 3

Eligibility


Inclusion Criteria:

   - Healthy women requesting contraception

   - 16-35 years old

   - Cohort 36-45 years old

   - Sexually active

Exclusion Criteria:

   - Currently pregnant, pregnant within 4 weeks prior to study entry or planning pregnancy
   within 24 months of study entry

   - Currently breastfeeding

   - Current persistent, abnormal vaginal bleeding

Ages Eligible for Study

16 Years - 45 Years

Genders Eligible for Study

Female

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Kathryn Batham
650-724-7826
Recruiting